SLU-PP-332 Research & Scientific Overview

Jump to: Structure | Mechanism | Studies | Pharmacokinetics | Protocols | Limitations | Lead Researcher | References

SLU-PP-332 Molecular Structure & Chemical Properties

SLU-PP-332 represents a breakthrough in exercise mimetic research as the first orally bioavailable pan-agonist of the estrogen-related receptors (ERRs) with sufficient pharmacokinetic properties for in vivo research applications. Developed in the early 2000s at Saint Louis University School of Medicine, this synthetic small molecule has emerged as one of the most extensively studied ERR agonists in preclinical metabolic research, with investigations spanning obesity, heart failure, skeletal muscle function, and mitochondrial dysfunction. Unlike earlier ERR modulators that were limited to in vitro studies due to poor bioavailability, SLU-PP-332 achieves measurable plasma and tissue concentrations following administration, enabling comprehensive in vivo evaluation of ERR activation’s therapeutic potential across multiple organ systems.

Chemical Structure

[IMAGE PLACEHOLDER] Insert 2D chemical structure image here Image URL: https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?cid=5338394&t=l Alt text: SLU-PP-332 molecular structure diagram showing benzohydrazide core linked to naphthalene moiety Source credit: PubChem Position: Center-aligned below heading

2D molecular structure (Source: PubChem)

Technical Specifications

The compound’s structure features a benzohydrazide core linked to a naphthalene moiety via a hydrazone bond, a scaffold specifically optimized for ERR receptor selectivity and pharmacological stability. This structural design enables the compound to cross biological membranes and reach target tissues including skeletal muscle, heart, liver, and kidney.

SLU-PP-332 Mechanism of Action

SLU-PP-332 functions as a pan-agonist of the estrogen-related receptors – ERRalpha, ERRbeta, and ERRgamma – with highest potency for ERRalpha (EC50: 98 nM), followed by ERRbeta (EC50: 230 nM) and ERRgamma (EC50: 430 nM). Despite the name, these orphan nuclear receptors are not directly involved in estrogen signaling but rather serve as master regulators of cellular energy metabolism, mitochondrial biogenesis, and oxidative capacity. Upon activation by SLU-PP-332, these receptors translocate to the nucleus and bind to specific DNA response elements, initiating transcription of hundreds of genes involved in aerobic metabolism, fatty acid oxidation, and mitochondrial function.

Primary Cellular Pathways

ERR-Mediated Gene Transcription – Exercise Mimetic Effects

Research has demonstrated that SLU-PP-332 activates an ERRalpha-dependent acute aerobic exercise genetic program in skeletal muscle tissue[1]. This transcriptional activation includes:

• Upregulation of DDIT4 (DNA damage-inducible transcript 4), a critical mediator of the exercise response
• Increased expression of PGC-1alpha (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master regulator of mitochondrial biogenesis
• Enhanced transcription of genes encoding mitochondrial respiratory chain proteins
• Activation of fatty acid oxidation pathway genes including PDK4 and FABP3

Studies using RNA sequencing revealed that SLU-PP-332 treatment altered expression of over 200 metabolic genes, with particular enrichment in pathways related to fatty acid metabolism, tricarboxylic acid cycle, and oxidative phosphorylation[2].

Mitochondrial Biogenesis and Respiratory Function

SLU-PP-332 significantly enhances mitochondrial function in multiple tissue types through ERR activation[1,2]. Key effects include:

• Increased mitochondrial number – studies documented elevated mitochondrial DNA copy numbers in treated muscle cells
• Enhanced respiratory capacity – isolated mitochondria from SLU-PP-332-treated animals showed increased oxygen consumption and ATP production
• Improved mitochondrial ultrastructure – electron microscopy revealed restored mitochondrial cristae organization in failing hearts
• Elevated oxidative enzyme activity – increased expression and activity of enzymes involved in the electron transport chain

In C2C12 myocyte cultures, SLU-PP-332 at 10 micromolar concentration increased both mitochondrial respiration and cellular oxygen consumption within 72 hours[1].

Metabolic Substrate Switching – Fatty Acid Preference

A defining characteristic of SLU-PP-332’s mechanism is its promotion of fatty acid oxidation as the primary fuel source, mimicking the metabolic shift observed during endurance exercise[2,3]. This involves:

• Upregulation of genes encoding fatty acid transport proteins (FABP3, CD36)
• Increased expression of beta-oxidation enzymes
• Enhanced activity of medium-chain acyl-CoA dehydrogenase (MCAD)
• Metabolomic analysis showed normalized fatty acid and lipid metabolite profiles in obese mouse hearts

The compound’s ability to shift cellular metabolism from glucose dependence to fatty acid utilization represents a key mechanism underlying its effects on energy expenditure and fat mass reduction.

Muscle Fiber Type Remodeling

SLU-PP-332 induces a shift in skeletal muscle fiber composition toward oxidative phenotypes[1]. Research documented:

• Increased Type IIa fibers – oxidative fast-twitch muscle fibers that combine endurance with power
• Decreased glycolytic Type IIb fibers
• Enhanced capillary density in muscle tissue
• Improved muscle fatigue resistance

This fiber type remodeling was ERRalpha-dependent, as demonstrated by loss of effect in ERRalpha knockout mice.

Autophagy and Cellular Quality Control

Recent investigations revealed that ERR activation by SLU-PP-332 promotes autophagy through transcription factor EB (TFEB) signaling[4]. This pathway:

• Enhances removal of damaged mitochondria (mitophagy)
• Reduces accumulation of dysfunctional cellular components
• Protects against cardiac fibrosis by promoting clearance of damaged cardiomyocytes
• Supports tissue remodeling and regeneration

The autophagy-promoting effects contribute to SLU-PP-332’s cardioprotective and anti-fibrotic properties observed in multiple organ systems.

[CALLOUT BOX – Highlighted] Key Mechanistic Insight: SLU-PP-332’s multi-tissue effects result from ERR activation’s fundamental role in cellular energetics. By targeting these master metabolic regulators, the compound simultaneously influences skeletal muscle, heart, liver, and kidney function – replicating the broad systemic benefits of physical exercise through a single molecular mechanism. [END CALLOUT BOX]

SLU-PP-332 Research Applications & Key Findings

Metabolic Syndrome and Obesity Research

Diet-Induced Obesity Models

Extensive research in diet-induced obese (DIO) mice demonstrated SLU-PP-332’s metabolic effects[2,3]. In 28-day dosing studies at 50 mg/kg twice daily (intraperitoneal), findings included:

• 12% reduction in body weight despite unchanged food intake
• 10-fold decrease in fat mass accumulation compared to vehicle-treated controls
• Significant reduction in adipocyte size – histological analysis revealed smaller, healthier fat cells
• Improved blood lipid profiles – decreased total cholesterol, high-density lipoprotein, and triglycerides
• Enhanced insulin sensitivity – improved glucose tolerance in glucose tolerance tests

Importantly, weight loss occurred through increased energy expenditure and fatty acid oxidation rather than appetite suppression, distinguishing this mechanism from conventional weight loss approaches.

Genetically Obese Models

In leptin-deficient ob/ob mice, a genetic model of severe obesity, SLU-PP-332 treatment for 12 days produced[3]:

• Reduced fat mass and improved metabolic parameters
• Decreased hepatic steatosis (fatty liver)
• Normalized expression of metabolic genes in liver and muscle
• Improved glucose metabolism despite genetic predisposition to diabetes

These findings suggested ERR activation could overcome even severe genetic metabolic defects.

Exercise Performance and Skeletal Muscle Research

Endurance Capacity Enhancement

SLU-PP-332 treatment significantly improved exercise endurance in sedentary mice without requiring physical training[1]. Research documented:

• Enhanced treadmill running capacity – treated mice ran substantially longer before exhaustion
• Increased oxidative fiber content in skeletal muscle
• Elevated expression of exercise-associated genes including Vegfa, Cox5a, and Ppargc1a
• Improved muscle oxidative capacity measured by mitochondrial enzyme activities

The endurance-enhancing effects were lost in ERRalpha knockout mice, confirming receptor specificity.

Muscle Fiber Composition

Immunohistochemical analysis revealed that SLU-PP-332 induced[1]:

• Increased proportion of Type IIa oxidative fast-twitch fibers
• Enhanced capillary density supporting improved oxygen delivery
• Elevated expression of myoglobin and oxidative enzymes
• Metabolic remodeling characteristic of endurance-trained muscle

These adaptations occurred without mechanical loading, demonstrating pure pharmacological mimicry of exercise-induced muscle plasticity.

Cardiovascular Research

Heart Failure Models

Studies in pressure overload-induced heart failure demonstrated remarkable cardioprotective effects[5]. Using transaortic constriction (TAC) models, research showed:

• Improved ejection fraction – significant recovery of cardiac contractile function
• Reduced cardiac fibrosis – decreased collagen deposition and scarring
• Increased survival rates – extended lifespan in heart failure models
• Normalized metabolic gene expression – restored expression of fatty acid metabolism genes
• Enhanced mitochondrial function – improved mitochondrial oxidative capacity and ATP production

Notably, ERR agonists improved cardiac function without preventing compensatory hypertrophy, suggesting specific metabolic rather than structural effects.

Cardiac Metabolism

Metabolomic profiling of failing hearts revealed that SLU-PP-332[5]:

• Normalized fatty acid and lipid metabolite profiles
• Restored tricarboxylic acid cycle intermediates
• Enhanced oxidative phosphorylation metabolites
• Increased expression of genes encoding fatty acid transport and oxidation enzymes

Genetic studies confirmed ERRgamma as the primary mediator of cardioprotection, though ERRalpha also contributed to beneficial effects.

Renal and Hepatic Research

Aging Kidney Studies

Research in aging kidney models demonstrated that ERR agonism reverses age-related mitochondrial dysfunction[6]. Key findings included:

• Restored mitochondrial function in aged kidney tissue
• Reduced inflammation and oxidative stress
• Decreased fibrosis and preserved kidney architecture
• Normalized expression of metabolic and inflammatory genes

These effects suggest potential applications in age-related kidney disease and preservation of renal function.

Hepatic Metabolism

While primarily studied for muscle and cardiac effects, liver-specific investigations revealed[3]:

• Reduced hepatic steatosis in fatty liver models
• Improved liver enzyme profiles
• Enhanced hepatic fatty acid oxidation
• Normalized expression of metabolic regulatory genes

The compound’s effects on liver metabolism likely contribute to systemic metabolic improvements observed in obesity models.

[CALLOUT BOX – Highlighted] Critical Research Limitation: All efficacy and safety data for SLU-PP-332 come exclusively from preclinical animal studies, primarily in mice. No human clinical trials have been conducted or published. The translation of these promising preclinical findings to human physiology, safety, and therapeutic efficacy remains completely unvalidated. [END CALLOUT BOX]

SLU-PP-332 Pharmacokinetics & Metabolism

Absorption & Distribution

SLU-PP-332 exhibits pharmacokinetic properties suitable for in vivo research applications, distinguishing it from earlier ERR modulators with poor bioavailability[1,2]. Following intraperitoneal administration in mice at 30-50 mg/kg:

• Plasma exposure – measurable concentrations of 0.2 micromolar detected 6 hours post-injection
• Tissue distribution – muscle tissue concentrations reached 0.6 micromolar, indicating preferential accumulation in metabolically active tissues
• Oral bioavailability – preliminary evidence suggests oral administration achieves systemic exposure, though complete pharmacokinetic characterization is lacking
• Tissue penetration – compound reaches target organs including skeletal muscle, heart, liver, and kidney

The compound’s ability to achieve physiologically relevant concentrations in vivo enabled the exercise mimetic and metabolic studies that defined its biological profile.

Metabolism & Elimination

The metabolic fate and elimination pathways of SLU-PP-332 remain incompletely characterized in published literature. Available data suggests:

• Plasma half-life – not fully defined; compound remains detectable 6 hours after administration but complete elimination kinetics unreported
• Duration of action – biological effects persist for hours after single dosing, with twice-daily administration maintaining therapeutic effects
• Metabolic pathways – likely undergoes hepatic metabolism, though specific enzymes and metabolites not characterized
• Accumulation potential – chronic dosing studies (28 days) showed no evidence of toxic accumulation

The relationship between pharmacokinetic parameters and pharmacodynamic effects requires further investigation, particularly regarding the duration of ERR activation relative to plasma concentrations.

Excretion Pathways

Excretion routes for SLU-PP-332 have not been systematically studied. Based on the compound’s chemical properties:

• Likely renal and/or biliary elimination of parent compound and metabolites
• No evidence of prolonged tissue retention in chronic dosing studies
• Clearance appears sufficient to prevent accumulation with twice-daily dosing regimens

Complete characterization of excretion pathways, metabolite profiles, and potential drug-drug interactions remains an important gap for future clinical translation.

SLU-PP-332 Research Protocols & Administration

Dosing in Published Research

Research investigations have employed specific SLU-PP-332 dosing regimens in mouse models:

• Standard regimen: 50 mg/kg body weight, administered intraperitoneally twice daily
• Single-dose studies: 25-50 mg/kg used for acute pharmacological assessments
• Duration: Chronic studies typically 12-28 days
• Concentration in culture: 10 micromolar for in vitro cell-based studies

Some investigators used 25 mg/kg twice daily for heart failure studies, demonstrating efficacy at this lower dose[5].

Important: These are experimental doses used in animal studies and cannot be extrapolated to other species due to significant differences in metabolism, receptor expression patterns, pharmacokinetics, body surface area-to-mass ratios, and drug clearance mechanisms. Species-specific factors profoundly influence both efficacy and safety profiles. Mouse metabolic rates and drug clearance are substantially higher than in humans, making direct dose translation inappropriate and potentially dangerous.

Administration Routes in Research

Multiple delivery methods have been investigated:

• Intraperitoneal injection – Primary route in published studies; provides reliable systemic delivery and controlled dosing
• Oral administration – Emerging evidence suggests oral bioavailability; investigations ongoing for oral formulation development
• Subcutaneous injection – Alternative parenteral route mentioned in some protocols, though less commonly used

The intraperitoneal route has been preferred in research settings for precise dose control and avoiding first-pass hepatic metabolism, though oral delivery would be required for any potential clinical application.

Common Model Organisms

SLU-PP-332 has been studied across multiple experimental systems:

• Mice – C57BL/6J strain – Primary animal model; used for metabolic, exercise, and cardiac studies
• Mice – ob/ob strain – Genetic obesity model; demonstrated efficacy in severe metabolic dysfunction
• Mice – diet-induced obese (DIO) – High-fat diet model; assessed effects on acquired obesity
• Cell culture systems – C2C12 myocytes (skeletal muscle cells), neonatal rat ventricular myocytes (cardiomyocytes), HEK293 cells (receptor activation assays)

All published efficacy data derives from rodent models, with no studies in larger animals or primates reported in peer-reviewed literature.

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite promising preclinical findings, SLU-PP-332 faces substantial translational barriers that significantly limit interpretation of its therapeutic potential and prevent any clinical application.

Lack of Human Clinical Data

The most significant limitation is the complete absence of human research:

• No human clinical trials exist in peer-reviewed literature or clinical trial registries
• No Phase I safety studies – human tolerability, maximum tolerated dose, and adverse event profile completely unknown
• No pharmacokinetic data in humans – absorption, distribution, metabolism, and elimination parameters uncharacterized
• No human efficacy data – whether metabolic or exercise-mimetic effects translate to human physiology is entirely speculative

All conclusions about potential therapeutic applications rest solely on mouse model data, which historically shows poor clinical translation rates for metabolic therapies.

Mechanistic Understanding Gaps

Fundamental aspects of SLU-PP-332’s mechanism require clarification:

• ERR isoform contributions – while ERRgamma appears critical for cardiac effects, the relative importance of each isoform across different tissues and conditions remains incompletely defined
• Off-target effects – whether the compound interacts with receptors or pathways beyond ERRs has not been comprehensively investigated
• Dose-response relationships – optimal dosing for different therapeutic applications unclear
• Long-term receptor modulation – effects of chronic ERR activation on receptor expression, sensitivity, and cellular adaptations not fully characterized

The compound’s pan-ERR activity raises questions about potential for undesired effects in tissues where selective isoform modulation might be preferable.

Long-Term Safety Considerations

Critical safety questions remain unanswered even in animal models:

• Chronic toxicity – studies extending beyond 28 days have not been published
• Reproductive and developmental effects – impact on fertility, pregnancy, and development unstudied
• Carcinogenic potential – chronic mitochondrial activation and metabolic reprogramming could theoretically influence cancer risk
• Cardiovascular safety – while improving heart failure metrics, effects on normal cardiac function and arrhythmia risk require investigation
• Drug-drug interactions – potential interactions with commonly used medications unknown

The absence of comprehensive toxicology studies represents a major barrier to clinical development.

Regulatory & Competitive Sport Status

FDA Position

SLU-PP-332 has not received FDA approval for any indication:

• Not approved for human or veterinary use
• Not recognized as safe for human consumption
• No established therapeutic use basis
• No legal pathway for medical prescription or compounding in the United States
• Classified as an investigational compound for research purposes only

The FDA has not issued specific guidance on SLU-PP-332, but as an unapproved compound, it cannot be legally marketed or prescribed for human use.

WADA Considerations

While not specifically listed by name in current WADA prohibited substance lists, SLU-PP-332 would likely fall under existing categories:

• Section S0 (Non-Approved Substances) – compounds in development not approved by regulatory authorities
• Potential S4 classification – metabolic modulators that alter energy metabolism
• Performance-enhancing potential – demonstrated endurance enhancement and metabolic effects in animal models

Athletes should consider SLU-PP-332 prohibited for competitive sport use until definitive regulatory guidance is established.

Research Classification: SLU-PP-332 is available only for laboratory research use. It is not intended for human consumption, medical use, or veterinary applications. All research must be conducted under appropriate ethical oversight and regulatory compliance with institutional review board approval where applicable.

Lead Researcher Spotlight

Dr. Cyrielle Billon, PhD

Professor of Pharmacology

University of Health Sciences & Pharmacy in St. Louis

Center for Clinical Pharmacology

St. Louis, Missouri, USA

Dr. Cyrielle Billon is a leading investigator in nuclear receptor pharmacology and has been instrumental in developing and characterizing SLU-PP-332 and related ERR agonists. She received her PhD in Integrative Molecular and Cellular Biology from the Ecole Normale Superieur of Lyon, France, and completed postdoctoral training at Saint Louis University School of Medicine under Dr. Thomas P. Burris.

Dr. Billon’s laboratory focuses on characterizing synthetic ligands for orphan nuclear receptors and their therapeutic potential in metabolic, cardiovascular, and inflammatory disorders. Her work has been critical in establishing ERR agonists as potential exercise mimetics and in demonstrating their efficacy across multiple disease models.

Key research contributions include:

• Development and characterization of SLU-PP-332 as the first in vivo-active ERR pan-agonist
• Demonstration of exercise-mimetic effects and metabolic syndrome alleviation in obese mouse models
• Investigation of ERR agonists’ cardioprotective mechanisms in heart failure
• Characterization of ERR-mediated transcriptional programs in skeletal muscle and cardiac tissue
• Exploration of autophagy regulation through ERR-TFEB signaling pathways

Her research program continues to investigate the therapeutic potential of ERR modulation for treating metabolic diseases, improving muscle function during aging, and addressing cardiovascular dysfunction. Dr. Billon’s work represents a bridge between basic nuclear receptor biology and translational therapeutic development.

Disclaimer: This spotlight is provided for educational purposes to acknowledge scientific contributions to SLU-PP-332 research. Cenexa Labs has no affiliation with Dr. Billon or the University of Health Sciences & Pharmacy, and this information does not constitute an endorsement of any products or services.

References

1. Billon, C., Sitaula, S., Banerjee, S., Welch, R.D., Elgendy, B., Hegazy, L., Maher, T., Ye, P., Shakya, S., Chatterjee, A., Yates, C.R., Malikzay, A., Alvarez, M., Griffett, K., Burris, T.P. (2023). Synthetic ERRalpha/beta/gamma Agonist Induces an ERRalpha-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chemical Biology, 18(4), 756-771. PubMed
   
2. Billon, C., Schoepke, E., Avdagic, A., Chatterjee, A., Butler, A.A., Elgendy, B., Walker, J.K., & Burris, T.P. (2024). A Synthetic ERR Agonist Alleviates Metabolic Syndrome. Journal of Pharmacology and Experimental Therapeutics, 388(2), 232-240. PubMed
   
3. Billon, C., Schoepke, E., Avdagic, A., Chatterjee, A., Butler, A.A., Elgendy, B., Walker, J.K., & Burris, T.P. (2023). A Synthetic ERR Agonist Alleviates Metabolic Syndrome. Journal of Pharmacology and Experimental Therapeutics, 388(2), 232-240. PubMed
   
4. Losby, M., Hayes, M., Valfort, A.C., Sopariwala, D.H., Sanders, R., Walker, J.K., Xu, W., Narkar, V.A., Zhang, L., Billon, C., & Burris, T.P. (2024). The Estrogen Receptor-Related Orphan Receptors Regulate Autophagy through TFEB. Molecular Pharmacology, 106(4), 164-172. PubMed
   
5. Xu, W., Billon, C., Li, H., Wilderman, A., Qi, L., Graves, A., Rideb, J., Zhao, Y., Hayes, M., Yu, K., Losby, M., Hampton, C.S., Adeyemi, C.M., Hong, S.J., Nasiotis, E., Fu, C., Oh, T.G., Fan, W., Downes, M., Welch, R.D., Evans, R.M., Milosavljevic, A., Walker, J.K., Jensen, B.C., Pei, L., Burris, T., & Zhang, L. (2024). Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation, 149(3), 227-250. PubMed
   
6. Wang, X.X., Myakala, K., Libby, A.E., Krawczyk, E., Panov, J., Jones, B.A., Bilan, V., Shults, N., Qi, Y., Krausz, K.W., Levi, M., & Gonzalez, F.J. (2023). Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney. American Journal of Pathology, 193(12), 1969-1987. PubMed
   

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. SLU-PP-332 is intended for laboratory research use only.